BP000284-CHM-252: Recombinant Human MIP-3 α (CCL20) , His Tag
Source: E. coli-derived.
A single, non-glycosylated, polypeptide chain containing 91 amino acids (27-96 a.a.) and having a molecular mass of 10.3 kDa.
Purity > 85%, by SDS-PAGE.BP000284-CHM-351: Recombinant Human MIP-3 α (CCL20)
Source: E. coli-derived.
A single, non-glycosylated, polypeptide chain containing 70 amino acids and having a molecular mass of 8 kDa.
Determined by its ability to chemoattract human T lymphocytes using a concentration range of 10.0 -50.0 ug/ml, corresponding to a specific activity of 20,000-100,000 units/mg.
Purity > 97%, by SDS-PAGE and RP-HPLC.BP000285-CHM-287: Recombinant Human MIP-3β (CCL19)
Source: E. coli-derived.
A single, non-glycosylated, polypeptide chain containing 77 amino acids and having a molecular mass of 8809 Dalton.
The Activity of CCL19 is calculated by the ability to chemoattract Human T cells using a concentration of 10-50ug/ml corresponding to a Specific Activity of 20,000-100,000IU/mg.
Purity > 98%, by SDS-PAGE and RP-HPLC.BP000286-CHM-341: Recombinant Mouse MIP-3β (CCL19)
Source: E. coli-derived.
The Activity is calculated by the ability to chemoattract Human mature dendritic cells using a concentration range of 8-80 ug/ml.
Purity > 98%, by SDS-PAGE and RP-HPLC.BP000286-CHM-322: Recombinant Human C-C Motif Chemokine 18 (CCL18) Portein
Source: E. coli-derived.
The activity is calculated by the ability to chemoattract Human T lymphocytes at 1-10ug/ml corresponding to a Specific Activity of 10,000-100,000 IU/mg.
Purity: > 97% by SDS-PAGE and RP-HPLC.BP000286-CHM-339: Recombinant Human C-C Motif Chemokine 18 (CCL18) Portein, His-Tag
Source: E. coli-derived.
A single, non-glycosylated, polypeptide chain containing 93 amino acids (22-89 a.a.) and having a molecular mass of 10.4 kDa.
Purity: > 95% by SDS-PAGE.BP000287-CHM-230: Recombinant Human MIP-5 (CCL15)
Source: E. coli-derived.
A single, non-glycosylated, polypeptide chain containing 92 amino acids and having a molecular mass of 10.1 kDa.
Determined by its ability to chemoattract human T-lymphocytes using a concentration range of 1-10 ug/ml corresponding to a Specific Activity of 10,000-100,000 IU/mg.
Purity > 97%, by SDS-PAGE and RP-HPLC.BP000288-CHM-348: Recombinant Human BCA-1/BLC (CXCL13)
Source: E. coli-derived.
Determined by its ability to chemoattract human B cells using a concentration range of 1-10 ug/ml corresponding to a Specific Activity of 10,000-100,000 IU/mg.
Purity > 97%, by SDS-PAGE and RP-HPLC.BP000289-CHM-001: Recombinant Human C-X-C Motif Chemokine Ligand 14 (CXCL14) Protein
Source: E. coli-derived.
The ED50 of CXCL14 as determined by its ability to induce calcium flux of prostaglandin E2 treated THP1 human acute monocytic leukemia cells was 1.0-10.0 ug/ml.
N-terminal sequence analysis: Ser-Lys-Cys-Lys-Cys.
Predicted molecular mass: 9.4 kDa.
Purity: > 95% by SDS-PAGE and RP-HPLC.BP000289-CHM-007: Recombinant Mouse C-X-C Motif Chemokine Ligand 14 (CXCL14) Protein
Source: E. coli-derived.
The ED50 of CXCL14 as determined by its ability to chemoattract activated monocytes was using a concentration range of 1.0-10.0 ug/ml.
Purity: > 95% by SDS-PAGE and RP-HPLC.